SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001725160-24-000097
Filing Date
2024-04-29
Accepted
2024-04-29 16:36:43
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A zntl-defa14acoverpagexinte.htm DEFA14A 18458
2 GRAPHIC a2024noticeofinternetavail.jpg GRAPHIC 387231
3 GRAPHIC a2024noticeofinternetavaila.jpg GRAPHIC 494756
  Complete submission text file 0001725160-24-000097.txt   1234026
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39263 | Film No.: 24891777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)